Investing in penny stocks requires not just patience, but an immense appetite for risk. U.S. equities are in the midst of a rally with the Nasdaq and S&P500 rising 7.97% and 7.02%, respectively, on a year-to-date basis. The Russell 2000 Index, which tracks the performance of small-cap companies, is up around 2.26% year-to-date. If penny-stock investors make wise investments, they could trounce the returns of the major indices. However, they could also lose all of their investment if they don’t do their due-diligence.

In this article, I will introduce three high-potential stocks penny stocks primed for explosive future growth. These stocks span different sectors and industries, but they all have one thing in common: they are disrupting their respective markets and have the potential to create value for their shareholders.

Canoo (GOEV)

Source: shutterstock.com/rafapress

Canoo (NASDAQ:GOEV) is a U.S.-based electric vehicle (EV) startup focusing on subscription-based mobility services. The company’s flagship product is the Canoo Lifestyle Vehicle, a futuristic-looking SUV that can seat up to seven people. In 2023, the EV start-up successfully delivered three Crew Transportation Vehicles (CTV) to NASA’s Kennedy Space Center in Florida. Subsequently, in 2024, the U.S. Postal Service announced that it would purchase 6 EVs from Canoo

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

The secret to the appeal of Canoo’s vehicles is their innovative chassis design. In particular, the EV startup’s vehicles are built on a proprietary skateboard platform, which integrates the battery, motor and other components into a modular chassis that can accommodate various body types and sizes.

The company is currently trading around 9 cents a share but could rise as more deals and partnerships get announced.

Cybin (CYBN)

Source: 24K-Production/Shutterstock

Cybin (NYSEMKT:CYBN), a clinical-stage biopharmaceutical company that develops psychedelic-based therapeutics for mental health conditions. While Cybin is still in the pre-revenue stage, the company has made meaningful strides in the development of CYB003 which will be able to treat major depressive disorder, CYB004 for generalized anxiety disorder and CYB005 to treat neuroinflammation. The California state legislature’s recent decision to decriminalize mushrooms as well as other natural psychedelics could eventually bring forth meaningful business growth and opportunities for Cybin in the future.

The stock is currently trading at 32 cents per share, which makes sense given the lack of substantial revenue. However, Cybin’s assets remain relatively robust, amounting to $39 million. The final stage of the clinical trials for CYB003 are on their way to completion, and the results could potentially breathe life into Cybin’s share value.